Patents by Inventor David Y. Jackson

David Y. Jackson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11400164
    Abstract: The invention provides an immunoconjugate of formula: or pharmaceutically acceptable salt thereof, wherein subscript r is an integer from 1 to 10, subscript n is an integer from about 2 to about 25, and “Ab” is an antibody construct that has an antigen binding domain that binds HER2. The invention further provides compositions comprising and methods of treating cancer with the immunoconjugate.
    Type: Grant
    Filed: September 2, 2021
    Date of Patent: August 2, 2022
    Assignees: Bolt Biotherapeutics, Inc., The Board of Trustees of The Leland Stanford Junior University
    Inventors: Shelley Erin Ackerman, Michael N. Alonso, David Y. Jackson, Arthur Lee, Edgar George Engleman
  • Patent number: 11229711
    Abstract: Provided herein are antibody-cytotoxin antibody-drug conjugates and related compounds, such as linker-cytotoxin conjugates and the linkers used to make them, and intermediates in their synthesis; compositions; and methods, including methods of treating cancers.
    Type: Grant
    Filed: June 6, 2014
    Date of Patent: January 25, 2022
    Assignee: Magenta Therapeutics, Inc.
    Inventors: David Y. Jackson, Edward Ha
  • Publication number: 20220001022
    Abstract: The invention provides an immunoconjugate of formula: or pharmaceutically acceptable salt thereof, wherein subscript r is an integer from 1 to 10, subscript n is an integer from about 2 to about 25, and “Ab” is an antibody construct that has an antigen binding domain that binds HER2. The invention further provides compositions comprising and methods of treating cancer with the immunoconjugate.
    Type: Application
    Filed: September 2, 2021
    Publication date: January 6, 2022
    Applicants: Bolt Biotherapeutics, Inc., The Board of Trustees of The Leland Stanford Junior University
    Inventors: Shelley Erin Ackerman, Michael N. Alonso, David Y. Jackson, Arthur Lee, Edgar George Engleman
  • Publication number: 20210284750
    Abstract: A method for producing an immunoconjugate, the method comprising combining one or more compounds of Formula I and an antibody of Formula II, wherein Formula II is an antibody with one or more lysine residues, in an aqueous solution buffered at a pH of about 7.5 to about 9 until at least 33 mol % of the one or more compounds of Formula I is conjugated to the antibody of Formula II to provide the immunoconjugate of Formula III, wherein Adj is an adjuvant, Z is —CH2—, —C(O)NH—, —C(O)O—, or —C(O)—, L is a linker, E is an ester, and r is the average number of adjuvants attached to the antibody and is a positive number up to about 8, in a first buffered aqueous solution.
    Type: Application
    Filed: April 16, 2018
    Publication date: September 16, 2021
    Applicant: Bolt Biotherapeutics, Inc.
    Inventors: David Y. Jackson, Michael N. Alonso, Arthur Lee, Richard P. Laura
  • Patent number: 11110178
    Abstract: The invention provides an immunoconjugate comprising an antibody construct which includes an antigen binding domain and an Fc domain, an adjuvant moiety, and a linker, wherein each adjuvant moiety is covalently bonded to the antibody via the linker. Methods for treating cancer with the immunoconjugates of the invention are also described.
    Type: Grant
    Filed: March 13, 2020
    Date of Patent: September 7, 2021
    Assignees: The Board of Trustees of the Leland Standford Junior University, BOLT BIOTHERAPEUTICS, INC.
    Inventors: Michael Nathaniel Alonso, Edgar George Engleman, Shelley Erin Ackerman, Justin Kenkel, Arthur Lee, David Y. Jackson
  • Publication number: 20210187115
    Abstract: The invention provides an immunoconjugate of formula: (I), or pharmaceutically acceptable salt thereof, wherein subscript r is an integer from 1 to 10, subscript n is an integer from about 2 to about 50, “Adj” is an adjuvant moiety, and “Ab” is an antibody construct that has an antigen binding domain that binds EGFR. The invention also provides compositions comprising the immunoconjugate. The invention further provides methods of treating cancer with the immunoconjugate.
    Type: Application
    Filed: August 29, 2019
    Publication date: June 24, 2021
    Applicants: Bolt Biotherapeutics, Inc., The Board of Trustees of The Leland Stanford Junior University
    Inventors: Michael N. Alonso, Edgar George Engleman, David Y. Jackson, Arthur Lee, Shelley Erin Ackerman
  • Publication number: 20210154316
    Abstract: The invention provides an immunoconjugate comprising (a) an antibody construct comprising (i) an antigen binding domain and (ii) an Fc domain and (b) 1-8 adjuvant cores, wherein each adjuvant core is covalently bonded to the antibody construct via a linker, wherein each adjuvant core comprises a 2-amino nitrogen moiety with a pendant nitrogen atom and a point of attachment of the linker to the adjuvant core, and wherein the distance between the pendant nitrogen atom and the point of attachment of the linker is greater than about 5 ?. The invention also provides methods for treating cancer with the immunoconjugates.
    Type: Application
    Filed: May 17, 2019
    Publication date: May 27, 2021
    Applicants: Bolt Biotherapeutics, Inc., The Board of Trustees of the Leland Stanford Junior University
    Inventors: Michael N. Alonso, David Y. Jackson, Brian Safina, Shelley Erin Ackerman, Edgar George Engleman
  • Publication number: 20210139596
    Abstract: Provided herein are modified antibodies, compounds used to make them, and intermediates in their synthesis; corn positions; formulations and methods, including methods of treating diseases, disorders or conditions, for example, cancer, in humans.
    Type: Application
    Filed: June 17, 2020
    Publication date: May 13, 2021
    Inventors: David Y. Jackson, Edward Ha
  • Publication number: 20200392108
    Abstract: Antibody-cytotoxin antibody-drug conjugates and related compounds, such as linker-cytotoxin conjugates and the linkers used to make them, tubulysin analogs, and intermediates in their synthesis; compositions; and methods, including methods of treating cancers.
    Type: Application
    Filed: December 27, 2019
    Publication date: December 17, 2020
    Inventors: David Y. Jackson, Edward Ha
  • Publication number: 20200206357
    Abstract: The invention provides an immunoconjugate comprising an antibody construct which includes an antigen binding domain and an Fc domain, an adjuvant moiety, and a linker, wherein each adjuvant moiety is covalently bonded to the antibody via the linker. Methods for treating cancer with the immunoconjugates of the invention are also described.
    Type: Application
    Filed: March 13, 2020
    Publication date: July 2, 2020
    Inventors: Michael Nathaniel Alonso, Edgar George Engleman, Shelley Erin Ackerman, Justin Kenkel, Arthur Lee, David Y. Jackson
  • Patent number: 10675358
    Abstract: The invention provides an immunoconjugate comprising an antibody construct which includes an antigen binding domain and an Fc domain, an adjuvant moiety, and a linker, wherein each adjuvant moiety is covalently bonded to the antibody via the linker. Methods for treating cancer with the immunoconjugates of the invention are also described.
    Type: Grant
    Filed: September 24, 2018
    Date of Patent: June 9, 2020
    Assignees: The Board of Trustees of the Leland Stanford Junior University, Bolt Biotherapeutics, Inc.
    Inventors: Michael Nathaniel Alonso, Edgar George Engleman, Shelley Erin Ackerman, Justin Kenkel, Arthur Lee, David Y. Jackson
  • Publication number: 20200108151
    Abstract: The invention provides an immunoconjugate comprising an antibody construct which includes an antigen binding domain and an Fc domain, an adjuvant moiety, and a linker, wherein each adjuvant moiety is covalently bonded to the antibody via the linker which comprises an ethylene glycol group or glycine residue. Methods for treating cancer with the immunoconjugates of the invention are also described.
    Type: Application
    Filed: December 20, 2019
    Publication date: April 9, 2020
    Applicant: Bolt Biotherapeutics, Inc.
    Inventors: David Y. Jackson, Michael Nathaniel Alonso, Arthur Lee
  • Publication number: 20190209704
    Abstract: The present disclosure provides novel linker-cytotoxin conjugates and antibody-drug conjugates, including homogenous antibody-drug conjugates, comprising the novel linker-cytotoxin conjugates.
    Type: Application
    Filed: October 19, 2015
    Publication date: July 11, 2019
    Inventors: David Y. JACKSON, Edward HA, Paul SAUER, Simeon BOWERS, Maureen Fitch Bruhns, Jorge Monteon, Christopher Behrens, Randall L. Halcomb
  • Publication number: 20190076547
    Abstract: The invention provides an immunoconjugate comprising an antibody construct which includes an antigen binding domain and an Fc domain, an adjuvant moiety, and a linker, wherein each adjuvant moiety is covalently bonded to the antibody via, the linker. Methods for treating cancer with the immunoconjugates of the invention are also described.
    Type: Application
    Filed: September 24, 2018
    Publication date: March 14, 2019
    Inventors: Michael Nathaniel Alonso, Edgar George Engleman, Shelley Erin Ackerman, Justin Kenkel, Arthur Lee, David Y. Jackson
  • Publication number: 20190015516
    Abstract: The invention provides an immunoconjugate comprising an antibody construct which includes an antigen binding domain and an Fc domain, an adjuvant moiety, and a linker, wherein each adjuvant moiety is covalently bonded to the antibody via the linker which comprises an ethylene glycol group or glycine residue. Methods for treating cancer with the immunoconjugates of the invention are also described.
    Type: Application
    Filed: September 12, 2018
    Publication date: January 17, 2019
    Applicant: Bolt Biotherapeutics, Inc.
    Inventors: David Y. Jackson, Michael Nathaniel Alonso, Arthur Lee
  • Publication number: 20180147294
    Abstract: Antibody-cytotoxin antibody-drug conjugates and related compounds, such as linker-cytotoxin conjugates and the linkers used to make them, tubulysin analogs, and intermediates in their synthesis; compositions; and methods, including methods of treating cancers.
    Type: Application
    Filed: July 5, 2017
    Publication date: May 31, 2018
    Inventors: David Y. JACKSON, Edward HA, Gary D. PROBST
  • Publication number: 20160303247
    Abstract: Antibody-cytotoxin antibody-drug conjugates and related compounds, such as linker-cytotoxin conjugates and the linkers used to make them, tubulysin analogs, and intermediates in their synthesis; compositions; and methods, including methods of treating cancers.
    Type: Application
    Filed: August 24, 2015
    Publication date: October 20, 2016
    Applicant: Igenica Biotherapeutics, Inc.
    Inventors: David Y. Jackson, Edward Ha
  • Publication number: 20140363454
    Abstract: Antibody-cytotoxin antibody-drug conjugates and related compounds, such as linker-cytotoxin conjugates and the linkers used to make them, tubulysin analogs, and intermediates in their synthesis; compositions; and methods, including methods of treating cancers.
    Type: Application
    Filed: June 6, 2014
    Publication date: December 11, 2014
    Applicant: Igenica Biotherapeutics, Inc.
    Inventors: David Y. Jackson, Edward Ha, Gary D. Probst
  • Patent number: 7947839
    Abstract: Bis 1,8 naphthalimide compounds including antibody drug conjugate (ADC) are described. Pharmaceutical compositions comprising an effective amount of a 1,8 bis-naphthalimide compound for treatment of hyperproliferative disorders and other disorders are described. Methods are described for killing or inhibiting the proliferation of tumor cells or cancer cells including administering to a patient an effective amount of a 1,8 bis-naphthalimide compound.
    Type: Grant
    Filed: January 30, 2006
    Date of Patent: May 24, 2011
    Assignee: Genentech, Inc.
    Inventors: Lewis J. Gazzard, Edward HyungSuk Ha, David Y. Jackson, Joann M. Um
  • Publication number: 20090325962
    Abstract: The compounds of the invention are inhibitors of alpha4 containing integrin-mediated binding to ligands such as VCAM-1 and MAdCAM.
    Type: Application
    Filed: August 21, 2009
    Publication date: December 31, 2009
    Applicant: Genentech, Inc.
    Inventors: David Y. Jackson, Frederick C. Sailes, Daniel P. Sutherlin